The European Medicines Agency Review of Pazopanib for the Treatment of Advanced Renal Cell Carcinoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use

On June 14, 2010, the European Commission issued a conditional marketing authorization valid throughout the European Union for pazopanib for the treatment of advanced renal cell carcinoma. Pazopanib is an antineoplastic agent that inhibits multiple receptor tyrosine kinases. The recommended oral dos...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2011-11, Vol.17 (21), p.6608-6614
Hauptverfasser:	NIETO, Maria, BORREGAARD, Jeanett, ERSBØLL, Jens, TEN BOSCH, George J. A, VAN ZWIETEN-BOOT, Barbara, ABADIE, Eric, SCHELLENS, Jan H. M, PIGNATTI, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Carcinoma, Renal Cell - drug therapy Clinical Trials as Topic Humans Kidney Neoplasms - drug therapy Kidneys Medical sciences Nephrology. Urinary tract diseases Pharmacology. Drug treatments Pyrimidines - adverse effects Pyrimidines - therapeutic use Sulfonamides - adverse effects Sulfonamides - therapeutic use Tumors of the urinary system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!